Company · CIK 0001652130 · SIC 2835 — In Vitro & In Vivo Diagnostic Substances · Nasdaq
Intellia Therapeutics, Inc. · NTLA
Insider activity reported against this company. All insider holders · On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 20, 2026 SForm 4 → | Aug 24, 4:05 pm EDT | John M LeonardPresident and CEO, Director | 22,675 | $12.65 | $286,819 | 1,147,064 | −1.94% | 10b5-1 |
| Jul 22, 2026 SForm 4 → | Jul 24, 5:26 pm EDT | Edward J Dulac IIIEVP, Chief Financial Officer | 8,111 | $11.25 | $91,249 | 148,175 | −5.19% | |
| Jul 2, 2026 SForm 4 → | Jul 6, 5:01 pm EDT | Edward J Dulac IIIEVP, Chief Financial Officer | 4,677 | $18.00 | $84,186 | 156,286 | −2.91% | 10b5-1 |
| Jul 1, 2026 SForm 4 → | Jul 6, 5:02 pm EDT | Michael P DubeVP, Chief Accounting Officer | 2,641 | $16.78 | $44,316 | 66,886 | −3.80% | |
| Jun 9, 2026 AForm 4 → | Jun 10, 7:08 pm EDT | Frank VerwielDirector | 9,200 | — | — | 35,148 | — | |
| Jun 9, 2026 AForm 4 → | Jun 10, 7:07 pm EDT | Georgia KerestyDirector | 9,200 | — | — | 41,083 | — | |
| Jun 9, 2026 AForm 4 → | Jun 10, 7:06 pm EDT | Jesse GoodmanDirector | 9,200 | — | — | 33,559 | — | |
| Jun 9, 2026 AForm 4 → | Jun 10, 7:02 pm EDT | Brian GoffDirector | 9,200 | — | — | 32,609 | — | |
| Jun 9, 2026 AForm 4 → | Jun 10, 7:01 pm EDT | Fred E CohenDirector | 9,200 | — | — | 216,653 | — | |
| Jun 9, 2026 AForm 4 → | Jun 10, 7:00 pm EDT | William J ChaseDirector | 9,200 | — | — | 143,893 | — | |
| Jun 9, 2026 AForm 4 → | Jun 10, 6:57 pm EDT | Muna BhanjiDirector | 9,200 | — | — | 36,403 | — | |
| Mar 6, 2019 PForm 4 → | Mar 12, 4:38 pm EDT | Andrew SchiermeierEVP, Dev and Corp Strategy | 7,500 | $15.72 | $117,875 | 7,500 | — | plan? late |
| Mar 1, 2019 AForm 4 → | Mar 5, 4:36 pm EST | Fred E CohenDirector | 10,000 | $16.89 | $168,936 | 10,000 | — | plan? |
| Jul 16, 2018 SForm 4 → | Jul 18, 8:40 am EDT | Jean Francois FormelaDirector | 6,686 | $31.17 | $208,397 | 0 | −100% | plan? |
| Jun 19, 2018 SForm 4 → | Jun 20, 12:03 pm EDT | Jean Francois FormelaDirector | 6,686 | $27.96 | $186,908 | 0 | −100% | plan? |
| May 16, 2018 JForm 5 → | Feb 14, 2019, 4:02 pm EST | Novartis Institutes for BioMedical Research, Inc. +110% Owner | 75,222 | — | — | 4,352,295 | — | plan? |
| May 16, 2018 SForm 4 → | May 17, 10:47 am EDT | Jean Francois FormelaDirector | 6,686 | $25.04 | $167,389 | 0 | −100% | plan? |
| May 14, 2018 SForm 4 → | May 15, 8:43 pm EDT | John M. LeonardPresident and CEO, Director | 8,400 | $24.00 | $201,600 | 0 | −100% | plan? |
| Mar 28, 2018 MForm 4 → | Mar 30, 10:20 am EDT | Graeme BellEVP, Chief Financial Officer | 8,000 | $13.48 | $107,840 | 21,400 | — | plan? |
| Mar 23, 2018 AForm 4 → | Mar 26, 5:12 pm EDT | Caroline DorsaDirector | 410 | $24.05 | $9,861 | 5,410 | — | plan? |
| Mar 20, 2018 SForm 4 → | Mar 22, 1:43 pm EDT | Jean Francois FormelaDirector | 39,245 | $23.87 | $936,743 | 0 | −100% | plan? |
| Jan 29, 2018 SForm 4 → | Jan 30, 5:28 pm EST | Caribou Biosciences, Inc.10% Owner | 550,645 | $26.78 | $14,746,273 | 3,994,355 | −12.1% | plan? |
| Dec 12, 2017 SForm 4 → | Dec 14, 12:19 pm EST | Novartis Institutes for BioMedical Research, Inc. +110% Owner | 1,523,000 | $18.30 | $27,870,900 | 4,129,903 | −26.9% | plan? |
| Dec 6, 2017 SForm 4 → | Dec 8, 5:27 pm EST | Nessan BerminghamPresident & CEO, Director | 336,783 | $20.78 | $7,000,019 | 458,250 | −42.4% | plan? |
| Nov 3, 2017 AForm 4 → | Nov 3, 11:54 am EDT | Graeme BellEVP, Chief Financial Officer | 5,000 | $22.04 | $110,217 | 13,400 | — | plan? |
| Sep 13, 2017 SForm 4 → | Sep 13, 6:29 pm EDT | Caribou Biosciences, Inc.10% Owner | 1,048,846 | — | — | 4,545,000 | — | plan? |
| Jul 7, 2017 SForm 4 → | Jul 11, 5:40 pm EDT | Jean Francois FormelaDirector | 150,000 | $16.24 | $2,435,440 | 3,579,788 | −4.02% | plan? |
| Jul 7, 2017 SForm 4 → | Jul 11, 5:37 pm EDT | Atlas Venture Fund IX, L.P. +210% Owner | 150,000 | $16.24 | $2,435,440 | 3,579,788 | −4.02% | plan? |
| Jun 2, 2017 AForm 4 → | Jun 5, 8:03 am EDT | Caroline DorsaDirector | 5,000 | $12.42 | $62,100 | 5,000 | — | plan? |
| Jun 2, 2017 AForm 4 → | Jun 5, 7:59 am EDT | Graeme BellEVP, Chief Financial Officer | 8,400 | $12.37 | $103,938 | 8,400 | — | plan? |
| Jun 1, 2017 AForm 4 → | Jun 5, 8:01 am EDT | Perry A KarsenDirector | 5,000 | $11.99 | $59,925 | 5,000 | — | plan? |
| Jun 1, 2017 AForm 4 → | Jun 5, 7:57 am EDT | Jose E RiveraEVP, General Counsel & Ops | 8,400 | $12.03 | $101,075 | 8,994 | — | plan? |
| Jun 1, 2017 AForm 4 → | Jun 5, 7:55 am EDT | John M. LeonardEVP, R&D, Director | 8,400 | $12.06 | $101,322 | 8,400 | — | plan? |
| Jun 1, 2017 AForm 4 → | Jun 5, 7:53 am EDT | Nessan BerminghamPresident & CEO, Director | 8,400 | $11.95 | $100,379 | 795,033 | — | plan? |
| Mar 9, 2017 SForm 4 → | Mar 13, 10:39 am EDT | Atlas Venture Associates IX, L.P. +110% Owner | 21,132 | $13.91 | $293,843 | 0 | −100% | plan? |
| Mar 9, 2017 SForm 4 → | Mar 13, 10:34 am EDT | Jean Francois FormelaDirector | 21,132 | $13.91 | $293,843 | 0 | −100% | plan? |
| Mar 3, 2017 JForm 4 → | Mar 7, 3:11 pm EST | Novartis Institutes for BioMedical Research, Inc. +110% Owner | 79,245 | — | — | 5,652,903 | — | plan? |
| Mar 3, 2017 JForm 4 → | Mar 7, 8:35 am EST | Atlas Venture Fund IX, L.P. +210% Owner | 700,000 | — | — | 3,729,788 | — | plan? |
| May 11, 2016 PForm 4 → | May 13, 4:58 pm EDT | ORBIMED ADVISORS LLC +3Director | 250,000 | $18.00 | $4,500,000 | 2,662,180 | +10.4% | plan? |
| May 11, 2016 CForm 4 → | May 13, 4:58 pm EDT | ORBIMED ADVISORS LLC +3Director | 2,412,180 | — | — | 2,412,180 | — | plan? |
| May 11, 2016 PForm 4 → | May 13, 6:15 am EDT | Temasek Holdings (Private) Ltd +310% Owner | 300,000 | $18.00 | $5,400,000 | 790,527 | +61.2% | plan? |
| May 11, 2016 CForm 4 → | May 13, 6:15 am EDT | Temasek Holdings (Private) Ltd +310% Owner | 490,527 | — | — | 490,527 | — | plan? |
| May 11, 2016 CForm 4 → | May 11, 7:01 pm EDT | Jean Francois FormelaDirector | 4,429,788 | — | — | 4,429,788 | — | plan? |
| May 11, 2016 CForm 4 → | May 11, 6:59 pm EDT | Atlas Venture Fund IX, L.P. +210% Owner | 4,429,788 | — | — | 4,429,788 | — | plan? |
| May 11, 2016 PForm 4 → | May 11, 6:57 pm EDT | Novartis Institutes for BioMedical Research, Inc. +110% Owner | 277,777 | $18.00 | $4,999,986 | 5,573,658 | +5.25% | plan? |
| May 11, 2016 CForm 4 → | May 11, 6:57 pm EDT | Novartis Institutes for BioMedical Research, Inc. +110% Owner | 5,295,881 | — | — | 5,295,881 | — | plan? |
| May 11, 2016 CForm 4 → | May 11, 6:40 pm EDT | Rachel E. HaurwitzDirector, 10% Owner | 5,419,040 | — | — | 5,593,846 | — | plan? |
| May 11, 2016 CForm 4 → | May 11, 6:38 pm EDT | Caribou Therapeutics Holdco, LLC +110% Owner | 5,419,040 | — | — | 5,593,846 | — | plan? |
| May 11, 2016 PForm 4 → | May 11, 6:36 pm EDT | Carl L GordonDirector | 250,000 | $18.00 | $4,500,000 | 2,662,180 | +10.4% | plan? |
| May 11, 2016 CForm 4 → | May 11, 6:36 pm EDT | Carl L GordonDirector | 2,412,180 | — | — | 2,412,180 | — | plan? |
| May 11, 2016 CForm 4 → | May 11, 6:33 pm EDT | Nessan BerminghamPresident & CEO, Director | 437,019 | — | — | 786,633 | — | plan? |
| May 11, 2016 PForm 4 → | May 11, 4:25 pm EDT | BAKER BROS. ADVISORS LP +3Other | 200,000 | $18.00 | $3,600,000 | 976,214 | +25.8% | plan? |
| May 11, 2016 CForm 4 → | May 11, 4:25 pm EDT | BAKER BROS. ADVISORS LP +3Other | 862,120 | — | — | 796,683 | — | plan? |
Reported at this company — derivatives (options, RSUs, warrants)
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 9, 2026 AForm 4 → | Jun 10, 7:08 pm EDT | Frank VerwielDirector | 13,300 | — | — | 13,300 | — | |
| Jun 9, 2026 AForm 4 → | Jun 10, 7:07 pm EDT | Georgia KerestyDirector | 13,300 | — | — | 13,300 | — | |
| Jun 9, 2026 AForm 4 → | Jun 10, 7:06 pm EDT | Jesse GoodmanDirector | 13,300 | — | — | 13,300 | — | |
| Jun 9, 2026 AForm 4 → | Jun 10, 7:02 pm EDT | Brian GoffDirector | 13,300 | — | — | 13,300 | — | |
| Jun 9, 2026 AForm 4 → | Jun 10, 7:01 pm EDT | Fred E CohenDirector | 13,300 | — | — | 13,300 | — | |
| Jun 9, 2026 AForm 4 → | Jun 10, 7:00 pm EDT | William J ChaseDirector | 13,300 | — | — | 13,300 | — | |
| Jun 9, 2026 AForm 4 → | Jun 10, 6:57 pm EDT | Muna BhanjiDirector | 13,300 | — | — | 13,300 | — | |
| Jan 23, 2019 AForm 4 → | Jan 24, 5:31 pm EST | Fred E CohenDirector | 38,000 | — | — | 38,000 | — | |
| Dec 18, 2018 AForm 4 → | Dec 20, 4:25 pm EST | Jose E RiveraEVP, General Counsel | 71,000 | — | — | 71,000 | — | |
| Dec 18, 2018 AForm 4 → | Dec 20, 4:23 pm EST | Andrew SchiermeierEVP, Dev and Corp Strategy | 81,000 | — | — | 81,000 | — | |
| Dec 18, 2018 AForm 4 → | Dec 20, 4:21 pm EST | John M. LeonardPresident and CEO, Director | 240,000 | — | — | 240,000 | — | |
| Dec 18, 2018 AForm 4 → | Dec 20, 4:16 pm EST | Glenn GoddardEVP, Chief Financial Officer | 17,750 | — | — | 17,750 | — | |
| Nov 1, 2018 AForm 4/A → | Dec 20, 4:15 pm EST | Glenn GoddardSee Remarks | 90,000 | — | — | 90,000 | — | |
| Nov 1, 2018 AForm 4 → | Nov 1, 6:37 pm EDT | Glenn GoddardSEE REMARKS | 90,000 | — | — | 90,000 | — | amended |
| Oct 29, 2018 AForm 4 → | Oct 31, 5:58 pm EDT | Jesse GoodmanDirector | 38,000 | — | — | 38,000 | — | |
| May 17, 2018 AForm 4 → | May 21, 12:59 pm EDT | Jean Francois FormelaDirector | 19,000 | — | — | 19,000 | — | |
| May 17, 2018 AForm 4 → | May 21, 12:56 pm EDT | Perry A KarsenDirector | 19,000 | — | — | 19,000 | — | |
| May 17, 2018 AForm 4 → | May 21, 12:54 pm EDT | Caroline DorsaDirector | 19,000 | — | — | 19,000 | — | |
| May 17, 2018 AForm 4 → | May 21, 12:51 pm EDT | Frank VerwielDirector | 19,000 | — | — | 19,000 | — | |
| May 1, 2018 AForm 4 → | May 2, 4:35 pm EDT | Andrew SchiermeierEVP, Corporate Strategy | 23,500 | — | — | 23,500 | — | |
| Mar 28, 2018 MForm 4 → | Mar 30, 10:20 am EDT | Graeme BellEVP, Chief Financial Officer | 8,000 | — | — | 202,000 | — | |
| Jan 25, 2018 AForm 4 → | Jan 29, 3:32 pm EST | John M. LeonardCEO, Director | 220,000 | — | — | 220,000 | — | |
| Jan 25, 2018 AForm 4 → | Jan 29, 3:31 pm EST | Graeme BellEVP, Chief Financial Officer | 25,000 | — | — | 25,000 | — | |
| Jan 25, 2018 AForm 4 → | Jan 29, 3:30 pm EST | Jose E RiveraEVP, General Counsel | 25,000 | — | — | 25,000 | — | |
| Dec 12, 2017 AForm 4 → | Dec 14, 4:08 pm EST | Jose E RiveraEVP, General Counsel | 72,500 | — | — | 72,500 | — | |
| Dec 12, 2017 AForm 4 → | Dec 14, 4:08 pm EST | John M. LeonardEVP, R&D, Director | 72,500 | — | — | 72,500 | — | |
| Dec 12, 2017 AForm 4 → | Dec 14, 4:07 pm EST | Nessan BerminghamPresident & CEO, Director | 292,500 | — | — | 292,500 | — | |
| Dec 12, 2017 AForm 4 → | Dec 14, 4:06 pm EST | Graeme BellEVP, Chief Financial Officer | 72,500 | — | — | 72,500 | — | |
| Jul 25, 2017 AForm 4 → | Jul 25, 4:49 pm EDT | Frank VerwielDirector | 38,000 | — | — | 38,000 | — | |
| Jul 25, 2017 AForm 4 → | Jul 25, 4:47 pm EDT | Moncef SlaouiDirector | 38,000 | — | — | 38,000 | — | |
| May 18, 2017 AForm 4 → | May 19, 5:14 pm EDT | Caroline DorsaDirector | 19,000 | — | — | 19,000 | — | |
| May 18, 2017 AForm 4 → | May 19, 5:12 pm EDT | Jean Francois FormelaDirector | 19,000 | — | — | 19,000 | — | |
| May 18, 2017 AForm 4 → | May 19, 5:10 pm EDT | Carl L GordonDirector | 19,000 | — | — | 19,000 | — | |
| May 18, 2017 AForm 4 → | May 19, 5:08 pm EDT | Perry A KarsenDirector | 19,000 | — | — | 19,000 | — | |
| Jan 6, 2017 AForm 4 → | Jan 10, 8:12 pm EST | Nicole HeifnerSVP, Accounting | 28,500 | — | — | 28,500 | — | |
| Jan 6, 2017 AForm 4 → | Jan 10, 8:11 pm EST | David V MorrisseySVP, Platform & Delivery Tech | 30,000 | — | — | 30,000 | — | |
| Jan 6, 2017 AForm 4 → | Jan 10, 8:09 pm EST | Thomas M. BarnesSVP, R&D eXtellia | 50,500 | — | — | 50,500 | — | |
| Jan 6, 2017 AForm 4 → | Jan 10, 8:07 pm EST | John M. LeonardEVP, R&D, Director | 95,000 | — | — | 95,000 | — | |
| Jan 6, 2017 AForm 4 → | Jan 10, 8:05 pm EST | Jose E RiveraEVP, General Counsel & Ops | 115,000 | — | — | 115,000 | — | |
| Jan 6, 2017 AForm 4 → | Jan 10, 8:03 pm EST | Nessan BerminghamPresident & CEO, Director | 270,000 | — | — | 270,000 | — | |
| Jan 3, 2017 AForm 4 → | Jan 5, 5:57 pm EST | Graeme BellEVP, Chief Financial Officer | 210,000 | — | — | 210,000 | — | |
| May 11, 2016 CForm 4 → | May 13, 4:58 pm EDT | ORBIMED ADVISORS LLC +3Director | 3,730,618 | — | — | 0 | — | |
| May 11, 2016 CForm 4 → | May 13, 6:15 am EDT | Temasek Holdings (Private) Ltd +310% Owner | 490,527 | — | — | 0 | — | |
| May 11, 2016 CForm 4 → | May 11, 7:01 pm EDT | Jean Francois FormelaDirector | 6,850,999 | — | — | 0 | — | |
| May 11, 2016 CForm 4 → | May 11, 6:59 pm EDT | Atlas Venture Fund IX, L.P. +210% Owner | 6,850,999 | — | — | 0 | — | |
| May 11, 2016 CForm 4 → | May 11, 6:57 pm EDT | Novartis Institutes for BioMedical Research, Inc. +110% Owner | 8,190,476 | — | — | 0 | — | |
| May 11, 2016 CForm 4 → | May 11, 6:40 pm EDT | Rachel E. HaurwitzDirector, 10% Owner | 8,380,951 | — | — | 0 | — | |
| May 11, 2016 CForm 4 → | May 11, 6:38 pm EDT | Caribou Therapeutics Holdco, LLC +110% Owner | 8,380,951 | — | — | 0 | — | |
| May 11, 2016 CForm 4 → | May 11, 6:36 pm EDT | Carl L GordonDirector | 3,730,618 | — | — | 0 | — | |
| May 11, 2016 CForm 4 → | May 11, 6:33 pm EDT | Nessan BerminghamPresident & CEO, Director | 675,883 | — | — | 0 | — | |
| May 11, 2016 CForm 4 → | May 11, 4:25 pm EDT | BAKER BROS. ADVISORS LP +3Other | 1,333,334 | — | — | 0 | — | |
| May 5, 2016 AForm 4 → | May 9, 5:49 pm EDT | Jean Francois FormelaDirector | 23,529 | — | — | 23,529 | — | |
| May 5, 2016 AForm 4 → | May 9, 5:47 pm EDT | Carl L GordonDirector, 10% Owner | 23,529 | — | — | 23,529 | — | |
| May 5, 2016 AForm 4 → | May 9, 5:44 pm EDT | Rachel E. HaurwitzDirector, 10% Owner | 23,529 | — | — | 23,529 | — | |
| May 5, 2016 AForm 4 → | May 9, 5:43 pm EDT | Perry A KarsenDirector | 31,764 | — | — | 31,764 | — | |
| May 5, 2016 AForm 4 → | May 9, 5:41 pm EDT | Caroline DorsaDirector | 15,176 | — | — | 15,176 | — |